{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:48:22Z","timestamp":1778809702189,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Turku Doctoral Programme of Molecular Medicine"},{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Weston Park Hospital Cancer Charity"},{"name":"Breast Cancer Now"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92841-9","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T10:57:48Z","timestamp":1742381868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use"],"prefix":"10.1038","volume":"15","author":[{"given":"Nataliia","family":"Petruk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Lopez-Guajardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikko","family":"Mella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jouko","family":"Sandholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arja","family":"Jukkola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katri S.","family":"Selander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"92841_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/path.4288","volume":"232","author":"MC Cummings","year":"2014","unstructured":"Cummings, M. C. et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J. Pathol. 232, 23\u201331. https:\/\/doi.org\/10.1002\/path.4288 (2014).","journal-title":"J. Pathol."},{"key":"92841_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10549-018-5002-9","volume":"173","author":"V Sopik","year":"2019","unstructured":"Sopik, V., Sun, P. & Narod, S. A. Predictors of time to death after distant recurrence in breast cancer patients. Breast Cancer Res. Tr. 173, 465\u2013474. https:\/\/doi.org\/10.1007\/s10549-018-5002-9 (2019).","journal-title":"Breast Cancer Res. Tr."},{"key":"92841_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10549-008-0086-2","volume":"115","author":"R Dent","year":"2009","unstructured":"Dent, R. et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Tr. 115, 423\u2013428. https:\/\/doi.org\/10.1007\/s10549-008-0086-2 (2009).","journal-title":"Breast Cancer Res. Tr."},{"key":"92841_CR4","doi-asserted-by":"publisher","unstructured":"Tjensvoll, K. et al. Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients. BMC Cancer. 19 https:\/\/doi.org\/10.1186\/s12885-019-6268-y (2019).","DOI":"10.1186\/s12885-019-6268-y"},{"key":"92841_CR5","doi-asserted-by":"publisher","unstructured":"Petruk, N. et al. CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases. Front. Immunol. 14 https:\/\/doi.org\/10.3389\/fimmu.2023.1179022 (2023).","DOI":"10.3389\/fimmu.2023.1179022"},{"key":"92841_CR6","doi-asserted-by":"publisher","unstructured":"Westbrook, J. A. et al. CAPG and GIPC1: breast Cancer biomarkers for bone metastasis development and treatment. JNCI-J Natl. Cancer I. 108 https:\/\/doi.org\/10.1093\/jnci\/djv360 (2016).","DOI":"10.1093\/jnci\/djv360"},{"key":"92841_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/path.5197","volume":"247","author":"JA Westbrook","year":"2019","unstructured":"Westbrook, J. A. et al. Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. J. Pathol. 247, 381\u2013391. https:\/\/doi.org\/10.1002\/path.5197 (2019).","journal-title":"J. Pathol."},{"key":"92841_CR8","doi-asserted-by":"publisher","unstructured":"Pavlovic, M. et al. Enhanced MAF oncogene expression and breast Cancer bone metastasis. JNCI-J Natl. Cancer I. 107 https:\/\/doi.org\/10.1093\/jnci\/djv256 (2015).","DOI":"10.1093\/jnci\/djv256"},{"key":"92841_CR9","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S1470-2045(17)30603-4","volume":"18","author":"R Coleman","year":"2017","unstructured":"Coleman, R. et al. Effect of amplification on treatment outcomes with adjuvant Zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01\/04) trial. Lancet Oncol. 18, 1543\u20131552. https:\/\/doi.org\/10.1016\/S1470-2045(17)30603-4 (2017).","journal-title":"Lancet Oncol."},{"key":"92841_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2018.02.004","volume":"94","author":"C Wilson","year":"2018","unstructured":"Wilson, C. et al. Adjuvant Zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study. Eur. J. Cancer. 94, 70\u201378. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.004 (2018).","journal-title":"Eur. J. Cancer"},{"key":"92841_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jbo.2018.09.008","volume":"13","author":"RE Coleman","year":"2018","unstructured":"Coleman, R. E. et al. Benefits and risks of adjuvant treatment with Zoledronic acid in stage II\/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01\/04). J. Bone Oncol. 13, 123\u2013135. https:\/\/doi.org\/10.1016\/j.jbo.2018.09.008 (2018).","journal-title":"J. Bone Oncol."},{"key":"92841_CR12","doi-asserted-by":"publisher","unstructured":"Paterson, A. H. G. et al. MAF amplification and adjuvant clodronate outcomes in early-stage breast cancer in NSABP B-34 and potential impact on clinical practice. JNCI Cancer Spectr. 5 https:\/\/doi.org\/10.1093\/jncics\/pkab054 (2021).","DOI":"10.1093\/jncics\/pkab054"},{"key":"92841_CR13","doi-asserted-by":"publisher","unstructured":"Silva-Vilches, C., Ring, S. & Mahnke, K. ATP and its metabolite adenosine as regulators of dendritic cell activity. Front. Immunol. 9 https:\/\/doi.org\/10.3389\/fimmu.2018.02581 (2018).","DOI":"10.3389\/fimmu.2018.02581"},{"key":"92841_CR14","doi-asserted-by":"publisher","unstructured":"Schneider, E. et al. Generation and function of non-cell-bound CD73 in inflammation. Front. Immunol. 10 https:\/\/doi.org\/10.3389\/fimmu.2019.01729 (2019).","DOI":"10.3389\/fimmu.2019.01729"},{"key":"92841_CR15","doi-asserted-by":"publisher","unstructured":"De Caluw\u00e9, A. et al. Neo-CheckRay: Radiation therapy and adenosine pathway Blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial. BMC Cancer. 21 https:\/\/doi.org\/10.1186\/s12885-021-08601-1 (2021).","DOI":"10.1186\/s12885-021-08601-1"},{"key":"92841_CR16","doi-asserted-by":"publisher","unstructured":"Xia, C. L., Yin, S. H., To, K. K. W. & Fu, L. W. CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol. Cancer. 22 https:\/\/doi.org\/10.1186\/s12943-023-01733-x (2023).","DOI":"10.1186\/s12943-023-01733-x"},{"key":"92841_CR17","doi-asserted-by":"publisher","unstructured":"Ma, X. L. et al. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K\/AKT signaling by inducing Rap1-mediated membrane localization of P110 and predicts poor prognosis. J. Hematol. Oncol. 12 https:\/\/doi.org\/10.1186\/s13045-019-0724-7 (2019).","DOI":"10.1186\/s13045-019-0724-7"},{"key":"92841_CR18","doi-asserted-by":"publisher","unstructured":"Messaoudi, N. et al. Prognostic value of CD73 expression in resected colorectal cancer liver metastasis. Oncoimmunology 9 https:\/\/doi.org\/10.1080\/2162402x.2020.1746138 (2020).","DOI":"10.1080\/2162402x.2020.1746138"},{"key":"92841_CR19","doi-asserted-by":"publisher","unstructured":"Petruk, N. et al. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer. Sci. Rep-Uk. 11 https:\/\/doi.org\/10.1038\/s41598-021-85379-z (2021).","DOI":"10.1038\/s41598-021-85379-z"},{"key":"92841_CR20","doi-asserted-by":"publisher","unstructured":"D\u2019Oronzo, S. et al. Natural history of stage II\/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences. J. Bone Oncol. 28 https:\/\/doi.org\/10.1016\/j.jbo.2021.100367 (2021).","DOI":"10.1016\/j.jbo.2021.100367"},{"key":"92841_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/jnci\/djy088","volume":"110","author":"W Sauerbrei","year":"2018","unstructured":"Sauerbrei, W., Taube, S. E., McShane, L. M., Cavenagh, M. M. & Altman, D. G. Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. Jnci-J Natl. Cancer I. 110, 803\u2013811. https:\/\/doi.org\/10.1093\/jnci\/djy088 (2018).","journal-title":"Jnci-J Natl. Cancer I"},{"key":"92841_CR22","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1096\/fj.201700217R","volume":"32","author":"A Mediero","year":"2018","unstructured":"Mediero, A., Wilder, T., Shah, L. & Cronstein, B. N. Adenosine A receptor (A2AR) stimulation modulates expression of semaphorins 4D and 3A, regulators of bone homeostasis. Faseb J. 32, 3487\u20133501. https:\/\/doi.org\/10.1096\/fj.201700217R (2018).","journal-title":"Faseb J."},{"key":"92841_CR23","doi-asserted-by":"publisher","unstructured":"Shih, Y. R. V. et al. Dysregulation of ectonucleotidase-mediated extracellular adenosine during postmenopausal bone loss. Sci. Adv. 5 https:\/\/doi.org\/10.1126\/sciadv.aax1387 (2019).","DOI":"10.1126\/sciadv.aax1387"},{"key":"92841_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/Atvbaha.119.313002","volume":"40","author":"NR Sutton","year":"2020","unstructured":"Sutton, N. R. et al. CD73 promotes Age-Dependent accretion of atherosclerosis. Arterioscl Throm Vas. 40, 61\u201371. https:\/\/doi.org\/10.1161\/Atvbaha.119.313002 (2020).","journal-title":"Arterioscl Throm Vas"},{"key":"92841_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/eji.201948432","volume":"51","author":"D Eichin","year":"2021","unstructured":"Eichin, D. et al. CD73 contributes to anti-inflammatory properties of afferent lymphatic endothelial cells in humans and mice. Eur. J. Immunol. 51, 231\u2013246. https:\/\/doi.org\/10.1002\/eji.201948432 (2021).","journal-title":"Eur. J. Immunol."},{"key":"92841_CR26","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jcmgh.2022.01.018","volume":"13","author":"T Hara","year":"2022","unstructured":"Hara, T. et al. CD73(+) epithelial progenitor cells that contribute to homeostasis and renewal are depleted in eosinophilic esophagitis. Cell. Mol. Gastroenterol. Hepatol. 13, 1449\u20131467. https:\/\/doi.org\/10.1016\/j.jcmgh.2022.01.018 (2022).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"92841_CR27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00428-019-02722-6","volume":"476","author":"B Cerbelli","year":"2020","unstructured":"Cerbelli, B. et al. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. Virchows Arch. 476, 569\u2013576. https:\/\/doi.org\/10.1007\/s00428-019-02722-6 (2020).","journal-title":"Virchows Arch."},{"key":"92841_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00428-020-02888-4","volume":"478","author":"K Tahkola","year":"2021","unstructured":"Tahkola, K. et al. Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer. Virchows Arch. 478, 209\u2013217. https:\/\/doi.org\/10.1007\/s00428-020-02888-4 (2021).","journal-title":"Virchows Arch."},{"key":"92841_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2021.08.006","volume":"157","author":"XD He","year":"2021","unstructured":"He, X. D. et al. Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer. Eur. J. Cancer. 157, 114\u2013123. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.006 (2021).","journal-title":"Eur. J. Cancer"},{"key":"92841_CR30","doi-asserted-by":"publisher","unstructured":"Tripathi, A. et al. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J. Immunother. Cancer. 8 https:\/\/doi.org\/10.1136\/jitc-2020-001467 (2020).","DOI":"10.1136\/jitc-2020-001467"},{"key":"92841_CR31","doi-asserted-by":"publisher","unstructured":"Chen, Y. H., Lu, H. I., Lo, C. M. & Li, S. H. CD73 promotes tumor progression in patients with esophageal squamous cell carcinoma. Cancers 13 https:\/\/doi.org\/10.3390\/cancers13163982 (2021).","DOI":"10.3390\/cancers13163982"},{"key":"92841_CR32","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00262-020-02820-4","volume":"70","author":"P Rocha","year":"2021","unstructured":"Rocha, P. et al. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol. Immun. 70, 1965\u20131976. https:\/\/doi.org\/10.1007\/s00262-020-02820-4 (2021).","journal-title":"Cancer Immunol. Immun."},{"key":"92841_CR33","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/annonc\/mdx730","volume":"29","author":"L Buisseret","year":"2018","unstructured":"Buisseret, L. et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Ann. Oncol. 29, 1056\u20131062. https:\/\/doi.org\/10.1093\/annonc\/mdx730 (2018).","journal-title":"Ann. Oncol."},{"key":"92841_CR34","doi-asserted-by":"publisher","first-page":"11091","DOI":"10.1073\/pnas.1222251110","volume":"110","author":"S Loi","year":"2013","unstructured":"Loi, S. et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc. Natl. Acad. Sci. USA. 110, 11091\u201311096. https:\/\/doi.org\/10.1073\/pnas.1222251110 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"92841_CR35","doi-asserted-by":"publisher","first-page":"E1239","DOI":"10.1073\/pnas.1718197115","volume":"115","author":"D Samanta","year":"2018","unstructured":"Samanta, D. et al. Chemotherapy induces enrichment of CD47\/CD73\/PDL1 immune evasive triple-negative breast cancer cells. P Natl. Acad. Sci. USA. 115, E1239\u2013E1248. https:\/\/doi.org\/10.1073\/pnas.1718197115 (2018).","journal-title":"P Natl. Acad. Sci. USA"},{"key":"92841_CR36","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1002\/jcp.23001","volume":"227","author":"M Takedachi","year":"2012","unstructured":"Takedachi, M. et al. CD73-generated adenosine promotes osteoblast differentiation. J. Cell. Physiol. 227, 2622\u20132631. https:\/\/doi.org\/10.1002\/jcp.23001 (2012).","journal-title":"J. Cell. Physiol."},{"key":"92841_CR37","doi-asserted-by":"publisher","unstructured":"Shupp, A. B., Kolb, A. D., Mukhopadhyay, D. & Bussard, K. M. Cancer metastases to bone: Concepts, mechanisms, and interactions with bone osteoblasts. Cancers 10 https:\/\/doi.org\/10.3390\/cancers10060182 (2018).","DOI":"10.3390\/cancers10060182"},{"key":"92841_CR38","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/s41401-021-00840-z","volume":"43","author":"Y Xing","year":"2022","unstructured":"Xing, Y. et al. Therapeutic efficacy and mechanism of CD73-TGF\u03b2 dual-blockade in a mouse model of triple-negative breast cancer. Acta Pharmacol. Sin. 43, 2410\u20132418. https:\/\/doi.org\/10.1038\/s41401-021-00840-z (2022).","journal-title":"Acta Pharmacol. Sin"},{"key":"92841_CR39","doi-asserted-by":"publisher","unstructured":"Zhan, J. H. et al. Regulation of CD73 on NAD metabolism: Unravelling the interplay between tumour immunity and tumour metabolism. Cell. Commun. Signal. 22 https:\/\/doi.org\/10.1186\/s12964-024-01755-y (2024).","DOI":"10.1186\/s12964-024-01755-y"},{"key":"92841_CR40","doi-asserted-by":"publisher","unstructured":"Hasmim, M. et al. SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC. Front. Immunol. 13 https:\/\/doi.org\/10.3389\/fimmu.2022.982821 (2022).","DOI":"10.3389\/fimmu.2022.982821"},{"key":"92841_CR41","doi-asserted-by":"publisher","unstructured":"Kordass, T., Osen, W. & Eichm\u00fcller, S. B. Controlling the immune suppressor: transcription factors and MicroRnAs regulating CD73\/NT5E. Front. Immunol. 9 https:\/\/doi.org\/10.3389\/fimmu.2018.00813 (2018).","DOI":"10.3389\/fimmu.2018.00813"},{"key":"92841_CR42","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1158\/1535-7163.Mct-21-0107","volume":"20","author":"M Wurm","year":"2021","unstructured":"Wurm, M. et al. A novel antagonistic CD73 antibody for Inhibition of the immunosuppressive adenosine pathway. Mol. Cancer Ther. 20, 2250\u20132261. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0107 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"92841_CR43","doi-asserted-by":"publisher","unstructured":"Kurago, Z. et al. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy. Front. Immunol. 14 https:\/\/doi.org\/10.3389\/fimmu.2023.1212209 (2023).","DOI":"10.3389\/fimmu.2023.1212209"},{"key":"92841_CR44","doi-asserted-by":"publisher","unstructured":"Turiello, R. et al. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. J. Immunother. Cancer 8 https:\/\/doi.org\/10.1136\/jitc-2020-001689 (2020).","DOI":"10.1136\/jitc-2020-001689"},{"key":"92841_CR45","doi-asserted-by":"publisher","unstructured":"Jiang, T. et al. Comprehensive evaluation of NT5E\/CD73 expression and its prognostic significance in distinct types of cancers. BMC Cancer. 18 https:\/\/doi.org\/10.1186\/s12885-018-4073-7 (2018).","DOI":"10.1186\/s12885-018-4073-7"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92841-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92841-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92841-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T10:57:55Z","timestamp":1742381875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92841-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92841"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92841-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9449"}}